BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 34338398)

  • 21. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
    Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
    J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cancer cell growth by oleanolic acid in multidrug resistant liver carcinoma is mediated via suppression of cancer cell migration and invasion, mitochondrial apoptosis, G2/M cell cycle arrest and deactivation of JNK/p38 signalling pathway.
    Gao C; Li X; Yu S; Liang L
    J BUON; 2019; 24(5):1964-1969. PubMed ID: 31786862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
    Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
    Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway.
    Liu HY; Dong TX; Li ZZ; Li TT; Jiang J; Zhu MW; An TT; Chen YD; Yang XH
    Neoplasma; 2021 Sep; 68(5):924-937. PubMed ID: 33998239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
    Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L
    Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpinia oxyphylla oil induces apoptosis of hepatocellular carcinoma cells via PI3K/Akt pathway in vitro and in vivo.
    Hui F; Qin X; Zhang Q; Li R; Liu M; Ren T; Zhao M; Zhao Q
    Biomed Pharmacother; 2019 Jan; 109():2365-2374. PubMed ID: 30551496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of prunetrin induced G2/M cell cycle arrest and apoptosis via Akt/mTOR/MAPK pathways in hepatocellular carcinoma cells.
    Abusaliya A; Bhosale PB; Kim HH; Park MY; Jeong SH; Lee S; Kim GS
    Biomed Pharmacother; 2024 May; 174():116483. PubMed ID: 38552440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
    Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
    Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
    Hua H; Zhu Y; Song YH
    Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
    Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
    J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.
    Wang L; Chen C; Feng S; Tian J
    Mol Med Rep; 2018 May; 17(5):7017-7026. PubMed ID: 29568863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
    Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
    BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liquiritin inhibits proliferation and induces apoptosis in HepG2 hepatocellular carcinoma cells via the ROS-mediated MAPK/AKT/NF-κB signaling pathway.
    Wang JR; Li TZ; Wang C; Li SM; Luo YH; Piao XJ; Feng YC; Zhang Y; Xu WT; Zhang Y; Zhang T; Wang SN; Xue H; Wang HX; Cao LK; Jin CH
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Oct; 393(10):1987-1999. PubMed ID: 31956937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathways.
    Han K; Li C; Zhang X; Shang L
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30996112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
    Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
    Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways.
    Song J; Guan Z; Song C; Li M; Gao Z; Zhao Y
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway.
    Wang SS; Chen YH; Chen N; Wang LJ; Chen DX; Weng HL; Dooley S; Ding HG
    Cell Death Dis; 2017 Mar; 8(3):e2688. PubMed ID: 28333142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of cancer susceptibility candidate 2 inhibited progression of hepatocellular carcinoma cells.
    Gao X; Du H; Zhang R; Li C; Wang H; Xuan Q; Liu D
    J Cell Physiol; 2019 Jun; 234(6):9008-9018. PubMed ID: 30362539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.